ENDOLOGIX INC's ticker is and the CUSIP is 29266SAA4. A total of 15 filers reported holding ENDOLOGIX INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $1,446,000,000 | +7.0% | 1,500,000 | 0.0% | 0.02% | -7.7% |
| Q4 2016 | $1,352,000,000 | -6.6% | 1,500,000 | 0.0% | 0.03% | +18.2% |
| Q3 2016 | $1,447,000,000 | +4.8% | 1,500,000 | 0.0% | 0.02% | -26.7% |
| Q2 2016 | $1,381,000,000 | +25.4% | 1,500,000 | 0.0% | 0.03% | +50.0% |
| Q1 2016 | $1,101,000,000 | -9.8% | 1,500,000 | 0.0% | 0.02% | -4.8% |
| Q4 2015 | $1,220,000,000 | +36.5% | 1,500,000 | +50.0% | 0.02% | +16.7% |
| Q3 2015 | $894,000,000 | -7.5% | 1,000,000 | 0.0% | 0.02% | +5.9% |
| Q2 2015 | $967,000,000 | -3.5% | 1,000,000 | 0.0% | 0.02% | -19.0% |
| Q1 2015 | $1,002,000,000 | +2.0% | 1,000,000 | 0.0% | 0.02% | +23.5% |
| Q4 2014 | $982,000,000 | +9.0% | 1,000,000 | 0.0% | 0.02% | +6.2% |
| Q3 2014 | $901,000,000 | -10.0% | 1,000,000 | 0.0% | 0.02% | -20.0% |
| Q2 2014 | $1,001,000,000 | +5.0% | 1,000,000 | 0.0% | 0.02% | +11.1% |
| Q1 2014 | $953,000,000 | – | 1,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 51,117,000 | $46,140,000 | 1.90% |
| PFM Health Sciences, LP | 6,445,000 | $5,809,000 | 0.16% |
| Partner Investment Management, L.P. | 84,000 | $76,000 | 0.10% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 5,562,000 | $5,013,000 | 0.09% |
| OAKTREE CAPITAL MANAGEMENT LP | 6,000,000 | $5,423,000 | 0.08% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,095,000 | $1,004,000 | 0.04% |
| ACUTA CAPITAL PARTNERS, LLC | 96,000 | $86,000 | 0.03% |
| UBS OCONNOR LLC | 1,500,000 | $1,352,000,000 | 0.03% |
| AMUNDI ASSET MANAGEMENT US, INC. | 7,305,000 | $6,557,000 | 0.02% |
| Citadel Advisors | 6,230,000 | $5,624,000 | 0.01% |